Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
NCT03017573

Prospective Biobanking Study in Cancer Patients Aiming at Better Understand the Link Between the Molecular Alterations of the Tumor Itself, Its Microenvironment and Immune Response (SCANDARE)

Led by Institut Curie · Updated on 2026-02-03

1050

Participants Needed

6

Research Sites

782 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

SCANDARE is a prospective biobanking study on tumor (+/- nodes), plasma and blood samples at different time points in ovarian, triple negative breast, Head and Neck Cancer, advanced stage treatment-naïve cervical or vulva cancer and sarcoma (breast angiosarcoma and uterine sarcoma) cancers. This study will allowed to identify new molecular and/or immunological biomarkers associated with clinical and biological features of the tumors. All patients will receive standard treatment according to the stage of the diseases and usual procédures.

CONDITIONS

Official Title

Prospective Biobanking Study in Cancer Patients Aiming at Better Understand the Link Between the Molecular Alterations of the Tumor Itself, Its Microenvironment and Immune Response (SCANDARE)

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Newly diagnosed treatment-nafve ovarian cancer patients eligible for surgery or neoadjuvant chemotherapy
  • Newly diagnosed treatment-nafve triple-negative breast cancer patients eligible for surgery or neoadjuvant chemotherapy
  • Newly diagnosed treatment-nafve head and neck cancer patients eligible for surgery
  • Newly diagnosed treatment-nafve vulva cancer or cervical cancer patients with stage Ia - IIa1 with nodal metastasis, postoperative positive margin or parametrial-vaginal involvement, or stage 61IIa2
  • Newly diagnosed treatment-nafve sarcoma cancer patients with breast angiosarcoma or uterine sarcoma eligible for surgery or systemic treatment
  • Male or female patients 18 years of age or older
  • Signed informed consent
Not Eligible

You will not qualify if you...

  • Patients younger than 18 years old
  • Patients with psychological, familial, sociological, or geographical conditions that may prevent following the study protocol and follow-up
  • Patients deprived of liberty or under legal guardianship
  • Patients not affiliated with the Social Security System

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 6 locations

1

Institut Bergonie

Bordeaux, France, 33076

Actively Recruiting

2

Centre Oscar Lambret

Lille, France, 59000

Actively Recruiting

3

Centre Leon Berard

Lyon, France, 69373

Actively Recruiting

4

Institut Curie

Paris, France, 75005

Actively Recruiting

5

Institut Curie Hopital Rene Huguenin

Saint-Cloud, France, 92210

Actively Recruiting

6

Institut de Cancérologie de Lorraine - Nancy

Vandœuvre-lès-Nancy, France

Not Yet Recruiting

Loading map...

Research Team

A

Anne-Sophie PLISSONNIER

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

BASIC_SCIENCE

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here